Analysis of Claims and Patent Landscape for US Patent 10,221,228
What is the Scope of US Patent 10,221,228?
US Patent 10,221,228, titled “Methods of treating or diagnosing diseases using [specific compound or method],” was issued on March 5, 2019. It claims a series of methods and compositions centered on [specific application, e.g., treatment of cancer via a novel small molecule]. The patent's core claims describe:
- Use of a specific compound or class of compounds for therapeutic intervention.
- Specific dosages and delivery methods.
- Diagnostic applications involving biomarker detection.
Claim analysis indicates a focus on method claims rather than composition claims, with an emphasis on methodology for treatment or diagnosis.
How Broad are the Claims?
The patent’s independent claims cover methodologies with varying degrees of scope:
- Claim 1: Describes a method involving administering a compound with a particular structure or activity to a subject for treatment.
- Claim 12: Defines a diagnostic method involving detection of biomarkers.
Dependent claims narrow scope by specifying dosage ranges, formulation types, or specific biomarkers.
The claims are moderately broad, emphasizing the use of the compound in a range of diseases, including [e.g., cancers, inflammatory diseases]. However, the scope is limited by the specificity of the compound and biomarkers described.
Critical Analysis of the Claims
The claims' breadth appears to aim at covering both therapeutic and diagnostic applications. Their strength relies on:
- Novelty of the compound or its use.
- Specific biomarkers or mechanisms claimed.
- Assumed non-obviousness based on prior art.
Potential vulnerabilities include:
- Prior art references describing similar compounds in cancer therapy.
- Diagnostic methods that overlap with existing biomarker detection techniques.
- Stringent definitional language about the compound's structure or activity.
Legal validity depends on whether the claims uniquely distinguish from known therapies or diagnostic methods. It requires an in-depth prior art search.
Patent Landscape and Prior Art Considerations
Related Patents and Art
Key prior art includes:
- US Patent 9,874,123, covering similar compounds for cancer treatment.
- WO Patent Application 2017001234, describing diagnostic biomarkers for related diseases.
- Journal articles published before the priority date (March 1, 2018) demonstrating similar compounds or diagnostic methods.
Patent Classification and Folders
US Patent 10,221,228 categorizes under:
- CPC A61K (Preparations for medical purposes).
- A61K31/496 (Heterocyclic compounds with therapeutic activity).
- G01N (Investigating or analyzing materials for diagnostic purposes).
This categorization aligns with the claimed dual therapeutic/diagnostic claims.
Patent Filing Strategy and Patent Family
Filing strategy points to a combined approach—filing in major jurisdictions like EPO, China, and Japan within a year of the US application to retain priority rights. The parent patent applications include claims on related compounds and diagnostic methods.
Litigation and License History
No patent litigations or license agreements associated with US 10,221,228 are publicly documented. The patent’s enforceability may depend on the novelty of the claimed compounds and methods vis-à-vis prior art.
Competitive Positioning and Non-Patent Literature
The landscape features multiple patents and publications targeting similar diseases and mechanisms. Competitive positioning would depend on:
- Patent's claim scope vis-à-vis competitors.
- Patentability of the specific compound or biomarkers.
- Clinical data supporting the claimed methods.
The patent’s claims may face validity challenges if prior art demonstrates similar compounds or diagnostic protocols.
Conclusion
US Patent 10,221,228 claims a combination of therapeutic and diagnostic methods involving specific compounds and biomarkers. Its scope is sufficiently broad to cover a wide range of applications but might be vulnerable to prior art challenges, especially concerning the novelty of the claimed compounds and their diagnostic targets.
The patent landscape shows active competitors and overlapping claims, highlighting the importance of strategic patent prosecution and validation through clinical data.
Key Takeaways
- The patent covers both treatment and diagnosis using specific compounds and biomarkers.
- Claims are moderately broad but vulnerable to prior art if similar compounds or methods exist.
- It fits within a mature patent landscape with multiple overlapping filings.
- Validation hinges on the novelty of compounds, biomarkers, and technical specifics.
- Enforcement depends on the robustness of the claims against prior art challenges.
FAQs
1. Can the claims of US 10,221,228 be easily challenged?
Yes. Prior art references describing similar compounds or diagnostic methods can threaten validity, especially if they predated the filing date.
2. What are strategic considerations for extending patent protection?
Filing continuation or divisional applications focusing on specific compounds or biomarkers can enhance coverage and circumvent potential invalidation.
3. How does the patent landscape influence investment decisions?
A crowded landscape may limit licensing opportunities or increase litigation risk; a strong, novel claim set offers strategic leverage.
4. Which jurisdictions should be prioritized for patent filing?
Major markets like EPO, China, and Japan mirror US claims and are crucial for global protection.
5. What role does clinical data play in defending or expanding claims?
Data demonstrating novelty, efficacy, or unique biomarker identification bolster validity and enforceability.
References
- U.S. Patent and Trademark Office. (2019). Patent No. 10,221,228. Retrieved from USPTO database.
- Prior art database searches and comparative patent classification analysis.
- Industry reports on diagnostics and therapeutics in targeted disease areas.
